Pinder named Cancer Moonshot Scholar by NCI
College of Medicine faculty member among first receiving honor
Leeya Pinder, MD, MPH, associate professor in the UC College of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, is among the first 11 people named as Cancer Moonshot Scholars by the National Cancer Institute (NCI).
The Cancer Moonshot Scholars program is designed to advance cancer science while also diversifying the pool of researchers and the approaches to cancer research that NCI funds. The program is supported by the White House’s Cancer Moonshot initiative and aligns with NCI’s Equity and Inclusion Program and NIH’s UNITE Initiative. The Cancer Moonshot Scholars program is led by the Center to Reduce Cancer Health Disparities. NCI intends to fund up to 30 additional Cancer Moonshot Scholars.
Leeya Pinder, MD, MPH, associate professor in the UC College of Medicine Department of Obstetrics and Gynecology. Photo/Dan Davenport/UC College of Medicine
Pinder’s project is “Repurposed Antiretroviral Therapies to Eliminate Cervical Cancer (POLESA Trial).” Her R37 is a seven-year award totaling $2.75 million during the first five years, with additional funding coming during the project’s last two years.
The overall goal of Pinder’s project is to find new, non-invasive, easily scalable solutions that address the profound gap in secondary cervical cancer prevention, particularly among women living with HIV. The study, which will enroll 180 women who present for cervical cancer screening in a Cervical Cancer Prevention Program clinic in Zambia, will also assess the safety and acceptability of a vaginal capsule containing the protease inhibitors lopinavir and ritonavir given alone or in combination with thermal ablation to treat screened women found with precancerous abnormalities that are eligible for ablative therapy.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.
Combination immunotherapy helps overcome melanoma treatment resistance
November 10, 2025
MSN highlighted research led by the University of Cincinnati Cancer Center's Trisha Wise-Draper showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.